New genetic insights into hypospadias: MAFB and CEBPA's role in urothelial growth
GA, UNITED STATES, March 25, 2025 / EINPresswire.com / -- A recent study has unveiled the critical roles of two transcription factors, MAFB and CEBPA, in the development of hypospadias, a common congenital malformation affecting male urethral development. The research reveals that MAFB and CCAAT/enhancer-binding protein alpha (CEBPA) regulate urothelial cell growth via the Wnt/β-catenin signaling pathway, offering new insights into the genetic mechanisms underlying this condition. These findings pave the way for innovative therapeutic strategies and a deeper understanding of the genetic and molecular foundations of hypospadias.
Hypospadias is characterized by an ectopic urethral opening and abnormal penile curvature, affecting approximately 1 in 200 live male births. While its origins are believed to stem from a combination of genetic and environmental factors, androgen signaling pathways are thought to play a significant role in the condition's development. Despite progress in identifying the genetic components, the precise molecular mechanisms remain poorly understood. Previous studies have suggested that the Wnt/β-catenin signaling pathway is involved in urethral development, but the specific contributions of transcription factors such as MAFB and CCAAT/enhancer-binding protein alpha (CEBPA) have yet to be fully explored. This gap in understanding highlights the need for in-depth research to elucidate the pathways involved in hypospadias.
On September 13, 2024, a study (DOI: 10.1016/j.gendis.2024.101432) published in Genes & Diseases and led by researchers from the Children's Hospital of Chongqing Medical University in China identified MAFB and CEBPA as crucial regulators of urothelial cell growth. By influencing cell proliferation and apoptosis through the Wnt/β-catenin signaling pathway, MAFB and CEBPA play a significant role in the genetic mechanisms of hypospadias. This research lays a strong foundation for future studies aimed at developing targeted therapies for this prevalent congenital condition.
The study focused on the roles of MAFB and CEBPA in urothelial cell growth, utilizing human foreskin samples and mouse models. The researchers found that expression levels of MAFB and CEBPA were significantly reduced in the foreskin tissues of hypospadias patients. Using RNA sequencing and Western blot analysis, they discovered that MAFB knockdown led to suppressed CEBPA protein expression, inhibiting the Wnt/β-catenin pathway and causing cell cycle arrest and increased apoptosis in urothelial cells. Furthermore, MAFB overexpression promoted cell proliferation and activated the Wnt/β-catenin pathway, while CEBPA knockdown reversed these effects. These findings highlight the pivotal role of the MAFB-CEBPA axis in regulating urothelial cell growth and suggest that disruptions in this pathway may contribute to hypospadias development. The study also pinpointed potential therapeutic targets for future interventions.
Dr. Xing Liu, the corresponding author of the study, commented, 'Our findings provide a deeper understanding of the molecular mechanisms underlying hypospadias. By identifying the roles of MAFB and CEBPA in urothelial growth, we have uncovered potential targets for therapeutic intervention, which could lead to improved outcomes for patients with this condition.'
The discovery of the MAFB-CEBPA regulatory pathway holds immense potential for advancing the treatment and prevention of hypospadias. By targeting this pathway, researchers could develop novel therapies to correct or prevent the malformation during early development. Additionally, the study opens exciting new avenues for exploring the genetic and molecular underpinnings of other congenital disorders related to urethral development. Future research may focus on identifying additional genetic factors and environmental influences that interact with the MAFB-CEBPA pathway, further advancing our understanding of hypospadias and related conditions.
DOI
10.1016/j.gendis.2024.101432
Original Source URL
https://doi.org/10.1016/j.gendis.2024.101432
Funding information
This work was financed by the National Natural Science Foundation of China (No. 81970571), the Natural Science Foundation of Chongqing Municipality, China (No. CSTB2022NSCQ-MSX1001), and the Program for Youth Innovation in Future Medicine, Chongqing Medical University (No. W0109).
Lucy Wang
Legal Disclaimer:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
China's AI chip tool QiMeng beats engineers, designs processors in just days
As the US-China tech war intensifies, both nations are racing to secure independence in critical technologies. With Washington tightening access to advanced chip tools, Beijing is ramping up efforts to break its reliance on Western software. In a major step, China's top scientific body has unveiled a homegrown, AI-powered system to automate chip design, an area long dominated by American firms. The Chinese Academy of Sciences (CAS) has launched an AI-driven chip design platform called QiMeng, meaning 'enlightenment' in Chinese. Developed by the State Key Laboratory of Processor, the Intelligent Software Research Centre, and the University of the Chinese Academy of Sciences, the system aims to accelerate semiconductor development and reduce dependency on human programmers. QiMeng leverages large language models to automate complex chip design tasks. The developers open-sourced the system on GitHub and published detailed technical documentation in a recent research paper. The team added that an autonomous-driving chip, which would take human engineers weeks to complete, could be produced by QiMeng in just a few days. QiMeng is built around three functional layers. The foundation is a domain-specific processor chip model. Above that is a design agent that handles both hardware and software aspects. The top layer contains various chip design applications. These components work together to support automated front-end design, generation of hardware description language, OS configuration, and compiler toolchain creation. The research paper notes that future iterations will boost the system's capacity for self-evolution. Using the platform, researchers have built two processors: QiMeng-CPU-v1, which is comparable to Intel's 486 chip, and QiMeng-CPU-v2, which aligns with Arm's Cortex A53. The launch of QiMeng comes at a time when the US is pressuring major electronic design automation (EDA) software vendors to stop selling to Chinese firms. Companies like Synopsys, Cadence, and Siemens EDA, who together held 82% of China's EDA market last year, have been hit by fresh export restrictions from the US Commerce Department, according to a Morgan Stanley report cited by SCMP. QiMeng is a direct attempt to replace reliance on these Western firms. 'The goal was to improve efficiency, reduce costs and shorten development cycles when compared to manual methods,' said the CAS team in their paper. The system also aims to enable rapid customisation of domain-specific chip architectures and software stacks. As AI advances demand more powerful chips, China's ability to design and fabricate them locally becomes crucial. While the country still lags behind Taiwan Semiconductor Manufacturing Company in advanced chip fabrication, efforts like QiMeng are intended to close the gap in design capabilities. The developers acknowledged remaining hurdles, citing 'constrained fabrication technology, limited resources and a diverse ecosystem.' Still, they hope QiMeng will help automate the full chip design and verification process in the long run.
New York Post
2 days ago
- New York Post
Transformative ‘med-cations' are the ultimate 2025 wellness trend
Biohacking, bloodwork, transcranial electro-stimulation and an alkalizing daily miso soup for breakfast might not sound like the sexiest way to spend your vacation. But health is wealth and a growing contingent of high-net-worth, leisure-class travelers are trading R&R for self-prescribed 'med-cations.' 'The trend of viewing vacations as investments in health and well-being is gaining momentum, with travelers increasingly seeking experiences that offer tangible health benefits,' Alejandro Bataller, vice president of SHA Mexico, which opened in January 2024. I visited the clinic, located in Costa Mujeres, Mexico, where I went through their intensive four-day Rebalance and Energize Program. The experience was less vacation, more exhaustive crash course in my overall health and functionality on a physical and psychological level. 3 It may look like a relaxation retreat but you'll leave poked, flushed and thoroughly scanned. Courtesy of SHA Wellness Clinic It came complete with blood panels, gut health dinners, ozone therapy and, of course, daily miso soup for breakfast. While I've never left such a beautiful place less relaxed, the experience left me both physically and spiritually altered. 'If you're gonna spend all this money on a vacation, you might as well be investing in your health,' a guest named 'Rick' told me over a bowl of pea ice cream and beetroot foam after a gut health talk one night. A Miami-based banker, Rick says he searched far and wide for a wellness resort that could help him get on the right track physically and mentally after experiencing what he described as 'burnout' from his job. Ultimately, it was SHA's integrative approach to wellness — connecting natural therapies and advanced medicine using cutting-edge technology to customize an itinerary to the needs and well-being of each guest — that sold him. 'I don't do yoga in my personal life, and I knew I needed something more than just mindfulness and meditation,' he said. 'I needed something more transformative and science-based to really move the needle.' 'I needed something more transformative and science-based to really move the needle.' 'Rick,' a guest of SHA. As more and more travelers like Rick place a premium on destinations that offer 'transformative' experiences rooted in both Eastern and Western science-based medicine, specialty resorts are popping up to serve them. Co-founded by self-help guru Tony Robbins and global hotelier Sam Nazarian, four new preventative health and longevity hotels and residences called the Estate will debut in 2026. 'We're rewriting the narrative by seamlessly integrating luxury, science and longevity into one transformative experience,' said Nazarian. 'This is about more than wellness; it's about giving people the tools to live longer, healthier and more fulfilling lives.' Cutting-edge treatments based on scientific medicine, the Estate will offer preventive, genetic and anti-aging programs that will be individually tailored to each guest. Partnering with industry leader Fountain Life, the Estate aims to become the largest ecosystem of preventative medicine and longevity centers in the world. 3 Tony Robbins' the Estate plans to turn back the clock with anti-aging programs. Handout 'The future of preventative health is personalized, proactive and purpose-driven, and the Estate is where that future comes to life,' Nazarian said. 'We're not just building destinations — we're building a legacy of well-being.' In partnership with Fountain Life, a company co-founded by Robbins that specializes in disease detection and prevention, services including full-body MRI scans, AI-enabled coronary CT scans, genome sequencing and advanced blood diagnostics aimed at optimizing the mental as well as physical well-being are just the tip of the 'We're at a tipping point in how people approach their health,' Nazarian added. 'Vacations are no longer just escapes; they're investments in wellness and longevity.' 3 The Estate has a goal of becoming the world's largest ecosystem of preventative medicine and longevity centers. Alamy Stock Photo Expanding its global presence in 2026, SHA will open a new location in the coastal Al Jurf region of the United Arab Emirates called SHA Island Emirates. 'This facility aims to create a sanctuary where guests can disconnect from urban life and focus on their health, offering programs that blend SHA's renowned integrative methods with the unique cultural and environmental aspects of the region,' said Bataller. 'Our goal is to create the sixth blue zone on the planet.' The starting rate at SHA Mexico is $5,770, including the 4-day Rebalance Program, SHA Nutrition plan, and in-room accommodations in an Ocean Front Deluxe room.
